Literature DB >> 7014981

Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.

S G Massry, D A Goldstein, H H Malluche.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7014981     DOI: 10.1038/ki.1980.154

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  3 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.

Authors:  Jessica E Miller; Csaba P Kovesdy; Keith C Norris; Rajnish Mehrotra; Allen R Nissenson; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2010-09-03       Impact factor: 3.754

3.  1.25(OH)2 cholecalciferol pulse therapy and the effects of different dialysis membranes on serum PTH levels of haemodialysis patients.

Authors:  M Boran; E Doruk; F Gönenç; S Cetin
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.